Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

Subscribe to Pharma in Focus

Sign Up Now

Pharma in Focus is considered essential daily reading in the Australian and NZ pharma industry.

In production for 12 years, it is emailed daily to more than 10,000 pharma industry professionals throughout Australia and NZ.

For just $429.95 a year (plus GST) Pharma in Focus puts you ahead of the game by delivering:

  • Key Aussie & NZ pharma news every working day
  • Daily in-depth features covering all aspects of pharma from drug approvals to employment issues
  • Full coverage and analysis of PBAC, PBS and TGA decisions
  • Ten survey-based white papers per year (total value $1500)

New to Pharma in Focus? Sign up below for your FREE two week trial.

Time to subscribe? Sign up below for your 12 month subscription.

Need multiple licenses? We have great corporate rates. Contact our friendly subscription managers on 02 9939 1881 or admin@pharmainfocus.com.au for our latest prices.

3 Simple Steps

1 Fill in your details below and submit

2 Make your subscription choice

3 Make your payment choice (Credit Card, Direct Deposit or Cheque)

Pipeline Monitor
New RA drug in view
A new rheumatoid arthritis drug from Sanofi and more good news for MSD on blockbuster Keytruda were highlights among pipeline decisions this week.
Perspective
MSD v PBAC: it's all about the data
It might have been short but MSD's statement on the revised draft report of the post-market review of ezetimibe spoke volumes on how treatment of PBS data can skew conclusions to potentially alarming effect.
Approvals Action
New hope for metabolic disease
Alexion's orphan therapy Kanuma has been approved by the TGA for metabolic disease lysomal acid lipase deficiency.